

Research Board of the Academy of Sciences and by others in this field. And that is why I am anxious to get on with the job.

Senator NELSON. Are you carrying on continuous discussions with the Pharmaceutical Manufacturers Association respecting this matter?

Dr. GODDARD. We have been, through the good offices of the National Academy of Sciences meeting on this, and, as I say, for many, many months now.

Senator NELSON. Has the Pharmaceutical Manufacturers Association made any specific proposal as to what kind of a compendium they would like to see?

Dr. GODDARD. Yes, sir.

Senator NELSON. Have you discussed with them who would publish it; would pay for it?

Dr. GODDARD. Yes.

Senator NELSON. What is—

Dr. GODDARD. Let me just state our position for the record. We feel that the Pharmaceutical Manufacturers Association should pay for it.

I have pointed out that this is an opportunity for them to exercise leadership. They state that they sell—that they manufacture, rather—95 percent of the drugs that are sold as prescription drugs. And I say, therefore, they should assume the burden of the additional 5 percent, pay for the publication of a compendium that will be useful to every physician in the country and provide him with comprehensive information on all of the drugs available.

The format we have discussed in some detail. There does seem to be a problem, I am told, from their point of view with a requirement that I wish to impose; namely, that the drugs be discussed under the generic heading, including a brief discussion of the important uses, the dosage, side effects, contraindications for the drug, followed then by a listing of the trade names of the drugs, the dosage forms, and the manufacturers.

Such a book would be cross indexed by both trade and generic name. But this does seem to be a stumbling block—at least I am told that it is.

Now, on the other hand, the people who have been advising me from the Drug Research Board and from the American Medical Association's Council on Drugs feel that this is the only way in which a comprehensive, intelligent job could be done. From just the standpoint of format, it seems necessary to do it this way, otherwise there is great duplication, you see. There may be many manufacturers—there are indeed, I think, some 42 firms or more which produce *rauwolfia serpentina* as a prescription drug, and I think that *Serpasil* under the generic name *reserpine* has 70 firms manufacturing it.

Well, it does not seem sensible to produce a volume that would have in 70 different places the description of a drug; that is, the active ingredient is identical.

Senator NELSON. I guess you address yourself to this question a little later in your statement, but if you produced a compendium, would you contemplate listing every single manufacturer of every drug?

Dr. GODDARD. I hesitate to say every single manufacturer, because, as the Senator knows, there are a number of manufacturers who do a very small intrastate business only, and I do think just as a practical limitation on size, you have to have a cutoff point somewhere. These in-